SLAMF7 and Miyoshi myopathy: At a low FPR (5%), proteomic prediction identified individuals at high risk for MM (FCRLB, QPCT, SLAMF7, TNFRSF17 and TNFSF13B; DR = 50%), non-Hodgkin lymphoma (BCL2, CXCL13, IL10, PDCD1 and SCG3; DR = 55%) and motor neuron disease (including CST5, EGFLAM, NEFL, PODXL2 and TMED10; DR = 29%).